FRANKFURT (Reuters) – Sanofi (NASDAQ:) said Friday that its multiple sclerosis drug candidate was shown to delay the worsening of a progressive form of the disease by 31%, as the French drugmaker looks to file for approval later this year.
The company said earlier this month that a late-stage trial of its drug candidate tolebrutinib was successful.